Union City, CA-based MicuRx Pharmaceuticals has closed a $10 million round of financing. The Morningside Group led the round of investment. MicuRx discovers and develops advanced antibacterial and antifungal drugs. "MicuRx has established a strong pipeline of research projects targeting optimization of validated antibiotic classes such as protein synthesis inhibitors," Mike Gordeev, Ph.D., executive vice president and chief scientific officer of MicuRx, said in a statement. "We are aggressively moving forward to implement our proprietary approach and expect to identify our first development candidates with significantly improved therapeutic potential on an accelerated timeline."
- see MicuRx's release for more on the financing